1584. Voxelotor as a Treatment of Persistent Hypoxia in the ICU.
Hypoxia is encountered frequently in the ICU as a result of a wide range of pathologic characteristics. The oxygen-hemoglobin dissociation curve describes hemoglobin's affinity for a given Po2 and factors affecting uptake and offload. Research in manipulating this relationship between hemoglobin and oxygen is sparing. Voxelotor is a hemoglobin oxygen-affinity modulator that is approved by the US Food and Drug Association for use in the management of sickle cell disease. We present two patients without sickle cell disease who underwent treatment with this novel agent to assist with chronic hypoxia and weaning of mechanical support.
1597. CT Scan Differences of Pulmonary TB According to Presence of Pleural Effusion.
Subpleural micronodules and interlobular septal thickening are common CT scan findings in TB pleural effusion. These CT scan features could help us differentiate between TB pleural effusion and nonTB empyema.
1598. The Economic Burden of Bronchiectasis: A Systematic Review.
作者: Jack M Roberts.;Vikas Goyal.;Sanjeewa Kularatna.;Anne B Chang.;Nitin Kapur.;James D Chalmers.;Pieter C Goeminne.;Francisco Hernandez.;Julie M Marchant.;Steven M McPhail.
来源: Chest. 2023年164卷6期1396-1421页
Bronchiectasis, a previously neglected condition, now has renewed research interest. There are a few systematic reviews that have reported on the economic and societal burden of bronchiectasis in adults, but none have reported on children. We undertook this systematic review to estimate the economic burden of bronchiectasis in children and adults.
1599. Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease.
作者: Joong-Yub Kim.;JiWon Park.;Yunhee Choi.;Taek Soo Kim.;Nakwon Kwak.;Jae-Joon Yim.
来源: Chest. 2023年164卷5期1108-1114页
Morbidity and mortality from nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing. Mycobacterium avium complex (MAC) is the most common cause of NTM-PD. Microbiological outcomes are widely used as the primary end point of antimicrobial treatment, but their long-term impact on prognosis is uncertain.
|